Tirzepatide telehealth moved fast in 2026. After the March Novo Nordisk settlement pushed several compounding-heavy platforms toward branded medications, the remaining cash-pay compounders got a lot more attention, and the chatter on forums, Reddit threads, and patient communities clarified quickly around a short list of names. This article captures that list, explains why each one shows up in real recommendations, and is honest about the tradeoffs.
1. HealthRX
The single fact that gets HealthRX into nearly every recommendation thread: compounded tirzepatide starting at $149 per month with free overnight shipping to all 50 states, dispensed from a named 503A pharmacy (Manifest Pharmacy in Greer, South Carolina) that publishes USP-797 compliance and lot-tracks each shipment from bench to door.
That last part matters more than it sounds. A lot of compounding telehealth brands don’t name their pharmacy at all. HealthRX names it, and Manifest holds LegitScript certification (cert 50087439), which is independently verifiable. Physicians review new assessments within roughly 24 hours. Pricing is published upfront. No membership tier, no hidden dispensing charge added at checkout.
The clinical trial data HealthRX references on its site is trial-sourced, not proprietary: SURMOUNT-1 showed approximately 21% mean body weight reduction at 72 weeks with tirzepatide. That number is from the trial, not a platform claim.
For someone who wants low cash-pay pricing, overnight delivery anywhere in the country, and a pharmacy they can actually look up, HealthRX checks every box before the others get a turn.
Compounded tirzepatide is not FDA-approved. This applies to every compounding-based entry on this list.
2. FormBlends
FormBlends targets a different buyer: someone who wants to see the actual purity certificate before injecting anything.
The platform publishes per-batch testing for its compounded GLP-1s, including HPLC purity scores, mass spec identity confirmation, and endotoxin and sterility results with named numbers. Very few telehealth GLP-1 providers do this publicly. Dispensing goes through an FDA-registered 503A compounding pharmacy, and a clinician reviews each case.
Pricing runs higher than HealthRX. Semaglutide sits around $299 per vial, tirzepatide around $349. For patients who view published lab documentation as non-negotiable, that premium is the point.
FormBlends also carries a broader catalog. Recovery peptides, longevity compounds, cognitive-support options, all under the same clinician-supervised model. If you want GLP-1 therapy now and plan to add other peptides later without switching providers, this is the only name on this list that handles both from one account.
Ships to 47 states, not 50. Worth checking your state before starting.
3. Mochi Health
Mochi is one of the few platforms staffed by board-certified obesity medicine physicians rather than general practitioners reviewing GLP-1 requests. That distinction comes up constantly in patient discussions about long-term monitoring.
Compounded semaglutide runs around $99 per month, compounded tirzepatide around $199. Structured check-ins are built into the program, not optional. The monitoring is heavier than most cash-pay competitors, which slows some patients down but reassures others.
Worth noting: it ships compounded medications and also helps with branded meds when insurance applies.
4. Hims & Hers
Hims & Hers exited compounded GLP-1s following the March 2026 Novo settlement and now routes tirzepatide patients toward Zepbound, the branded FDA-approved version, at roughly $399 per month cash. With insurance and the Lilly savings card, that figure can drop to between $0 and $25 for eligible patients.
The platform is the right choice for anyone whose priority is FDA-approved branded medication and who has insurance worth running through a prior-auth process. Large support infrastructure, app-based tracking, fast onboarding.
Cash price without coverage is the highest on this list. Eyes open.
5. Henry Meds
Henry Meds operates on a cash-pay compounding model with unusually fast fulfillment. Shipping typically runs 24 to 72 hours. First-month pricing lands around $179 to $249 depending on the medication and dose.
The monitoring structure is lighter than Mochi’s. Some patients prefer that. Others, especially those with more complex metabolic histories, might want a more hands-on clinical setup. Henry gets recommended most often by people who want to get started quickly without a lot of intake friction.
No contracts.
6. Ro Body
Ro’s program runs roughly $39 for the first month and $74 to $149 per month after that, with medications billed separately on top of that fee. They maintain a prior-authorization team specifically for insurance-covered branded GLP-1s, which is genuinely useful for patients with commercial insurance who haven’t tried the prior-auth process yet.
The platform is better suited to someone who wants branded medication and has insurance than to a cash-pay patient focused on lowest total monthly cost. Medication billing is separate from membership, so read the total carefully before comparing it to flat-rate cash-pay competitors.
Common Questions
Is compounded tirzepatide from any of these clinics actually the same drug as Zepbound?
Not exactly. Compounded tirzepatide uses the same active molecule, but it is not FDA-approved and does not go through the same manufacturing oversight as Zepbound. Platforms like FormBlends publish third-party purity and sterility testing to close some of that gap, but the regulatory status is different regardless of test results.
Which of these platforms will actually name their compounding pharmacy, and why does that matter?
HealthRX publicly names Manifest Pharmacy in Greer, South Carolina, and lists its LegitScript certification number. Most telehealth GLP-1 providers do not disclose their pharmacy partner at all. Knowing the pharmacy lets you verify its registration with your state board and confirm it holds relevant certifications independently, rather than taking the platform’s word for it.
If I have commercial insurance, which of these is most likely to get tirzepatide covered?
Hims & Hers and Ro Body both have infrastructure for prior-authorization and insurance navigation. Hims & Hers routes patients to Zepbound, and the Lilly savings card can bring cash cost down to $0 to $25 per month for eligible patients. The cash-pay compounders on this list, including HealthRX, Henry Meds, and Mochi, are not designed around insurance billing.
How does Mochi Health’s physician model differ from what the other platforms here offer?
Mochi staffs board-certified obesity medicine specialists rather than general practitioners. That specialty training covers metabolic disease, not just prescription review. The structured check-ins are mandatory rather than optional. For patients with a longer weight history or comorbidities, that clinical depth is the main reason Mochi shows up in recommendations over cheaper, lighter-touch options.
Can I combine tirzepatide from one of these clinics with other peptides or compounds without switching providers?
FormBlends is the only platform on this list that pairs GLP-1 therapy with a broader compounded catalog, including recovery peptides and longevity compounds, under one clinician-supervised account. The other providers listed here focus on GLP-1s specifically. If stacking multiple compounds under one provider matters to you, FormBlends is the only option here that supports it.
A Note Before You Start
This article reflects publicly available pricing and platform information as of mid-2026. Pricing changes, formularies change, and compounding regulations are still in flux following recent FDA enforcement activity. Any GLP-1 medication, branded or compounded, requires a prescription from a licensed physician and carries real side effects that a clinician should walk through with you before you begin. Nothing here is medical advice.
Sources
- FDA warning letters to compounding telehealth firms, early 2026 (FDA.gov enforcement actions)
- Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide obesity trial, 72-week outcomes)
- Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide weight management trial)
- Novo Nordisk compounding settlement announcement, March 9, 2026 (Novo Nordisk press release)
- LegitScript certification registry (LegitScript.com)
- Publicly listed pricing pages for each platform named, accessed 2026
